Adherence, persistence, and switching patterns of dabigatran etexilate

American Journal of Managed Care

Volumn 19, Issue 9, 2013, Pages

  Tsai, Kimberly ^a   Erickson, Sara C ^a   Yang, Jianing ^a   Harada, Ann S M ^a   Solow, Brian K ^a   Lew, Heidi C ^a  

^a OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DATA BASE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MEDICATION PERSISTENCE; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; DRUG DATABASE; MEDICARE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTICOAGULANTS; BENZIMIDAZOLES; DATABASES, PHARMACEUTICAL; DRUG SUBSTITUTION; FACTOR XA INHIBITORS; HUMANS; MEDICARE PART D; MEDICATION ADHERENCE; PYRIDINES; RETROSPECTIVE STUDIES; UNITED STATES; WARFARIN;

EID: 84887251860     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47.
2. Vegter S, Nguyen NH, Visser ST, et al. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609-616.
3. Platt AB, Localio AR, Brensinger CM, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853-860.
4. Fitch K, Broulette J, Pyenson BS, Iwasaki K, Kwong WJ. Utilization of anticoagulation therapy in Medicare patients with nonvalvular atrial fibrillation. Am Health Drug Benefits. 2012;5(3):157-168.
5. Stanek E, Agatep BC, Herrera V, et al. Assessment of initial U.S. dabigatran utilization and short-term persistence [abstract]. Circulation.2011;124:A16675.
6. Michel J, Mundell D, Boga T, Sasse A. Dabigatran for anticoagulation in atrial fibrillation-early clinical experience in a hospital population and comparison to trial data. Heart Lung Circ. 2013;22(1):50-55.
7. Von Korff M, Wagner E, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): 1139-1151.
9. Theodorou AA, Palmieri A, Szychowski JA, Sehman ML, Swarna V. Prescription utilization of the oral anticoagulants. Am J Pharm Benefits. 2012;4(3):120-123.
10. Kirley K, Qato DM, Kornfield R, Stafford SS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5)615-621.